BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34570885)

  • 21. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
    Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
    Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
    Satgé D
    Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SON inhibits megakaryocytic differentiation via repressing RUNX1 and the megakaryocytic gene expression program in acute megakaryoblastic leukemia.
    Vukadin L; Kim JH; Park EY; Stone JK; Ungerleider N; Baddoo MC; Kong HK; Richard A; Tran J; Giannini H; Flemington EK; Lim SS; Ahn EE
    Cancer Gene Ther; 2021 Sep; 28(9):1000-1015. PubMed ID: 33247227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice.
    Ishihara D; Hasegawa A; Hirano I; Engel JD; Yamamoto M; Shimizu R
    Exp Hematol Oncol; 2024 Feb; 13(1):24. PubMed ID: 38409186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcription factor GATA-1 and Down syndrome leukemogenesis.
    Muntean AG; Ge Y; Taub JW; Crispino JD
    Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of GATA1 dysfunction to multi-step leukemogenesis.
    Shimizu R; Yamamoto M
    Cancer Sci; 2012 Dec; 103(12):2039-44. PubMed ID: 22937757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of GATA1 mutations in Down syndrome.
    Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
    Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular insights into Down syndrome-associated leukemia.
    Vyas P; Crispino JD
    Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissecting stepwise mutational impairment of megakaryopoiesis in a model of Down syndrome-associated leukemia.
    Evans EJ; DeGregori J
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35838049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling.
    Emmrich S; Rasche M; Schöning J; Reimer C; Keihani S; Maroz A; Xie Y; Li Z; Schambach A; Reinhardt D; Klusmann JH
    Genes Dev; 2014 Apr; 28(8):858-74. PubMed ID: 24736844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of erythroid-specific genes in megakaryoblastic disorders.
    Ito E; Kasai M; Toki T; Arai K; Yokoyama M
    Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
    Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
    Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute Megakaryocytic Leukemia.
    McNulty M; Crispino JD
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.
    Stankiewicz MJ; Crispino JD
    Blood; 2009 Apr; 113(14):3337-47. PubMed ID: 19168790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.